These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 27889344)

  • 1. Malabsorption of a Bioresorbable Vascular Scaffold System Leading to Very Late In-Scaffold Restenosis More Than 3.5 Years After Implantation: Assessment by Optical Coherence Tomography.
    Dommasch M; Langwieser N; Laugwitz KL; Ibrahim T
    JACC Cardiovasc Interv; 2016 Dec; 9(24):2571-2572. PubMed ID: 27889344
    [No Abstract]   [Full Text] [Related]  

  • 2. Bioresorbable vascular scaffold implantation for treatment of recurrent in-stent restenosis: insights from optical coherence tomography.
    Camuglia AC; Lavi S
    Int J Cardiol; 2014 Mar; 172(1):238-9. PubMed ID: 24447733
    [No Abstract]   [Full Text] [Related]  

  • 3. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study.
    Ormiston JA; Serruys PW; Onuma Y; van Geuns RJ; de Bruyne B; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Hebert KM; Rapoza R; Garcia-Garcia HM
    Circ Cardiovasc Interv; 2012 Oct; 5(5):620-32. PubMed ID: 23048057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neointimal proliferation is associated with clinical restenosis 2 years after fully bioresorbable vascular scaffold implantation.
    Indolfi C; Mongiardo A; Spaccarotella C; Caiazzo G; Torella D; De Rosa S
    Circ Cardiovasc Imaging; 2014 Jul; 7(4):755-7. PubMed ID: 25027457
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes.
    Serruys PW; Onuma Y; Ormiston JA; de Bruyne B; Regar E; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Miquel-Hebert K; Rapoza R; García-García HM
    Circulation; 2010 Nov; 122(22):2301-12. PubMed ID: 21098436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unfavorable bioresorbable vascular scaffold resorption, a cause of restenosis?
    Ishida K; Giacchi G; Brugaletta S; García-Álvarez A; Sabaté M
    Cardiovasc Revasc Med; 2016 Dec; 17(8):571-573. PubMed ID: 27345841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-in-human description of everolimus-eluting bioabsorbable vascular scaffold implantation for the treatment of drug-eluting stent failure: insights from optical coherence tomography.
    Grasso C; Attizzani GF; Patané M; Ohno Y; Capodanno D; Tamburino C
    Int J Cardiol; 2013 Oct; 168(4):4490-1. PubMed ID: 23890924
    [No Abstract]   [Full Text] [Related]  

  • 8. Serial optical coherence tomography of drug-eluting stent in-stent restenosis treated with the Absorb bioresorbable scaffold: an effective treatment?
    Farooq V; Mamas MA; Fraser DG; El-Omar M; Clarke B; Fath-Ordoubadi F
    EuroIntervention; 2015 Mar; 10(11):e1. PubMed ID: 25798636
    [No Abstract]   [Full Text] [Related]  

  • 9. First reported use of drug-coated balloon for bioresorbable in-scaffold restenosis.
    Latini RA; Buccheri D; Cortese B
    Catheter Cardiovasc Interv; 2017 Mar; 89(4):676-678. PubMed ID: 27649683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optical coherence tomography assessment of late intra-scaffold dissection: a new challenge of bioresorbable scaffolds.
    Ohno Y; Mangiameli A; Attizzani GF; Capodanno D; Tamburino C
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt A):e11-2. PubMed ID: 25499307
    [No Abstract]   [Full Text] [Related]  

  • 11. Edge vascular response after percutaneous coronary intervention: an intracoronary ultrasound and optical coherence tomography appraisal: from radioactive platforms to first- and second-generation drug-eluting stents and bioresorbable scaffolds.
    Gogas BD; Garcia-Garcia HM; Onuma Y; Muramatsu T; Farooq V; Bourantas CV; Serruys PW
    JACC Cardiovasc Interv; 2013 Mar; 6(3):211-21. PubMed ID: 23517830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results.
    Verheye S; Ormiston JA; Stewart J; Webster M; Sanidas E; Costa R; Costa JR; Chamie D; Abizaid AS; Pinto I; Morrison L; Toyloy S; Bhat V; Yan J; Abizaid A
    JACC Cardiovasc Interv; 2014 Jan; 7(1):89-99. PubMed ID: 24139932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late-acquired scaffold malapposition and discontinuity that may be attributable to pathological coronary ectasia: Insights from optical coherence tomography.
    Miyazaki T; Ruparelia N; Kawamoto H; Sato K; Latib A; Colombo A
    Int J Cardiol; 2015; 186():136-8. PubMed ID: 25818756
    [No Abstract]   [Full Text] [Related]  

  • 14. The Absorb Limits.
    Gómez Menchero AE; Camacho Freire SJ; Díaz Fernández JF; Roa Garrido J; León Jiménez J; Cardenal Piris R
    J Invasive Cardiol; 2016 Oct; 28(10):E122-E123. PubMed ID: 27705895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis: 5-Year Follow-Up.
    Serruys PW; Ormiston J; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Chevalier B; Smits P; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Wasungu L; Ediebah D; Veldhof S; Onuma Y
    J Am Coll Cardiol; 2016 Feb; 67(7):766-76. PubMed ID: 26892411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optical Coherence Tomography of Magnesium Bioresorbable Scaffold Restenosis.
    García-Blas S; Miñana G; Sanchis J
    Rev Esp Cardiol (Engl Ed); 2018 Dec; 71(12):1069. PubMed ID: 29223376
    [No Abstract]   [Full Text] [Related]  

  • 17. Recurrent Neoatherosclerosis After Bioresorbable Vascular Scaffold Treatment of In-Stent Restenosis.
    Bastante T; Rivero F; Benedicto A; Cuesta J; Alfonso F
    JACC Cardiovasc Interv; 2015 Aug; 8(9):1264-1265. PubMed ID: 26292592
    [No Abstract]   [Full Text] [Related]  

  • 18. Early (before 6 months), late (6-12 months) and very late (after 12 months) angiographic scaffold restenosis in the ABSORB Cohort B trial.
    Nakatani S; Onuma Y; Ishibashi Y; Muramatsu T; Iqbal J; Zhang YJ; van Geuns RJ; Ormiston JA; Serruys PW
    EuroIntervention; 2015 Mar; 10(11):1288-98. PubMed ID: 24572936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of acute expansion of bioresorbable vascular scaffolds versus metallic drug-eluting stents in different degrees of calcification: An Optical Coherence Tomography Study.
    Ming Fam J; van Der Sijde JN; Karanasos A; Felix C; Diletti R; van Mieghem N; de Jaegere P; Zijlstra F; Jan van Geuns R; Regar E
    Catheter Cardiovasc Interv; 2017 Apr; 89(5):798-810. PubMed ID: 27717119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.